Failure to follow-up after ophthalmology appointments can damage patients’ health, a new study suggests. “In our view, national consideration should be given to create targets for reporting how well providers are managing follow-up patients,” reported A Davis and colleagues in the journal Eye.
A silicone punctal plug-based delivery system for ophthalmic medications (Evolute, Mati Therapeutics) provides precisely controlled medication release into the tear film and has been associated with positive results in initial clinical testing.
A 19-month, open-label study of a novel bimatoprost, sustained-release ocular insert shows good safety and efficacy. The insert is polymer ring that sits atop the eye in the conjunctival fornix. Phase III trials are expected to begin in 2017.
OSD is of significant concern in patients with glaucoma on multiple topical medications. Optimal treatment of this condition with minimizing the intensity as well as with additional pharmacologic treatments for OSD can improve visual acuity and compliance and result in better outcomes both medically and regarding patient satisfaction.
The advent of low-risk surgical options is moving glaucoma from a pharmaceutically managed disease to one controlled via a series of surgical procedures. The outcome appears to be highly beneficial for patients, says Robert J. Noecker, MD.
America may face a public health crisis in coming years unless drastic changes are not made to the public perception of eye health, according to a report from the National Academies of Sciences, Engineering, and Medicine (NASEM). Taking steps to create a public conversation about the matter, Allergan has launched a public awareness campaign, See America, to improve this awareness of and access to comprehensive eye exams.